Gierlinger Gregor, Rech Lavinia, Emani Sitaram M, Del Nido Pedro J, Friehs Ingeborg
Department of Cardiac Surgery, Boston Children's Hospital, Harvard Medical School.
Department of Cardiac Surgery, Boston Children's Hospital, Harvard Medical School;
J Vis Exp. 2023 Jul 21(197). doi: 10.3791/65426.
Endocardial fibroelastosis (EFE), defined by subendocardial tissue accumulation, has major impacts on the development of the left ventricle (LV) and precludes patients with congenital critical aortic stenosis and hypoplastic left heart syndrome (HLHS) from curative anatomical biventricular surgical repair. Surgical resection is currently the only available therapeutic option, but EFE often recurs, sometimes with an even more infiltrative growth pattern into the adjacent myocardium. To better understand the underlying mechanisms of EFE and to explore therapeutic strategies, an animal model suitable for preclinical testing was developed. The animal model takes into consideration that EFE is a disease of the immature heart and is associated with flow disturbances, as supported by clinical observations. Thus, the heterotopic heart transplantation of neonatal rat donor hearts is the basis for this model. A neonatal rat heart is transplanted into an adolescent rat's abdomen and connected to the recipient's infrarenal aorta and inferior vena cava. While perfusion of the coronary arteries preserves the viability of the donor heart, flow stagnation within the LV induces EFE growth in the very immature heart. The underlying mechanism of EFE formation is the transition of endocardial endothelial cells to mesenchymal cells (EndMT), which is a well-described mechanism of early embryonic development of the valves and septa but also the leading cause of fibrosis in heart failure. EFE formation can be macroscopically observed within days after transplantation. Transabdominal echocardiography is used to monitor the graft viability, contractility, and the patency of the anastomoses. Following euthanasia, the EFE tissue is harvested, and it shows the same histopathological characteristics as human EFE tissue from HLHS patients. This in vivo model allows for studying the mechanisms of EFE development in the heart and testing treatment options to prevent this pathological tissue formation and provides the opportunity for a more generalized examination of EndMT-induced fibrosis.
心内膜弹力纤维增生症(EFE),由心内膜下组织积聚所定义,对左心室(LV)的发育有重大影响,并使患有先天性严重主动脉瓣狭窄和左心发育不全综合征(HLHS)的患者无法接受根治性解剖双心室手术修复。手术切除是目前唯一可用的治疗选择,但EFE常复发,有时会以更浸润性的生长方式侵入相邻心肌。为了更好地理解EFE的潜在机制并探索治疗策略,开发了一种适合临床前测试的动物模型。该动物模型考虑到EFE是一种未成熟心脏的疾病,并且如临床观察所支持的那样与血流紊乱有关。因此,新生大鼠供体心脏的异位心脏移植是该模型的基础。将新生大鼠心脏移植到青春期大鼠的腹部,并连接到受体的肾下主动脉和下腔静脉。虽然冠状动脉灌注可维持供体心脏的活力,但左心室内的血流停滞会在非常不成熟的心脏中诱导EFE生长。EFE形成的潜在机制是心内膜内皮细胞向间充质细胞的转变(EndMT),这是瓣膜和间隔早期胚胎发育的一种已充分描述的机制,但也是心力衰竭中纤维化的主要原因。移植后数天内即可在宏观上观察到EFE的形成。经腹超声心动图用于监测移植物的活力、收缩性和吻合口的通畅情况。安乐死后,采集EFE组织,其显示出与HLHS患者的人类EFE组织相同的组织病理学特征。这种体内模型允许研究心脏中EFE发育的机制,并测试预防这种病理性组织形成的治疗方案,为更广泛地研究EndMT诱导的纤维化提供了机会。